VIM

Across TCGA pan-cancer cohorts, VIM Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated VIM data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher VIM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VIM expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

ESCA, LIHC, and PRAD are the cancer types where VIM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.179	0.704	<.001	27	view →
LIHC	OS	Median	All	0.158	0.674	<.001	17	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	DFS	Median	All	0.870	0.369	.025	4	view →
BLCA	DFS	Median	IV	0.126	0.479	.007	3	view →
LUAD	OS	Median	II,III,IV	0.237	0.709	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

VIM–ESCA (OS)

Open the ESCA breakdown →